Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 79.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 78,989 shares of the medical equipment provider’s stock after selling 312,545 shares during the quarter. Envestnet Asset Management Inc. owned about 0.12% of Lantheus worth $6,629,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in LNTH. Fairfield Bush & CO. acquired a new position in shares of Lantheus during the 1st quarter valued at $177,000. Raymond James & Associates acquired a new position in shares of Lantheus during the 1st quarter valued at $856,000. Bank of New York Mellon Corp lifted its holdings in shares of Lantheus by 2.7% during the 1st quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider’s stock valued at $34,791,000 after acquiring an additional 16,422 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Lantheus by 14.4% during the 1st quarter. American Century Companies Inc. now owns 19,235 shares of the medical equipment provider’s stock valued at $1,064,000 after acquiring an additional 2,427 shares in the last quarter. Finally, HighTower Advisors LLC acquired a new position in shares of Lantheus during the 1st quarter valued at $354,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of Lantheus stock opened at $68.20 on Friday. The firm has a market cap of $4.67 billion, a PE ratio of 47.69 and a beta of 0.66. The firm’s 50-day simple moving average is $66.53 and its 200-day simple moving average is $77.25. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.05 and a current ratio of 5.37. Lantheus Holdings, Inc. has a 1 year low of $47.46 and a 1 year high of $100.85.

Insider Activity

In other news, President Paul Blanchfield sold 408 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $66.10, for a total value of $26,968.80. Following the sale, the president now owns 90,067 shares in the company, valued at approximately $5,953,428.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, President Paul Blanchfield sold 408 shares of the business’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $66.10, for a total transaction of $26,968.80. Following the completion of the sale, the president now owns 90,067 shares of the company’s stock, valued at approximately $5,953,428.70. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Mary Anne Heino sold 11,780 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $63.72, for a total transaction of $750,621.60. Following the sale, the chief executive officer now directly owns 317,687 shares of the company’s stock, valued at approximately $20,243,015.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,783 shares of company stock worth $1,015,296. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on LNTH shares. Truist Financial reiterated a “buy” rating and issued a $110.00 price objective on shares of Lantheus in a report on Wednesday, October 4th. JMP Securities cut their price objective on shares of Lantheus from $130.00 to $100.00 and set a “market outperform” rating on the stock in a report on Friday, November 3rd. B. Riley reiterated a “buy” rating and issued a $113.00 price objective on shares of Lantheus in a report on Tuesday, October 3rd. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Monday, November 6th. Finally, William Blair started coverage on shares of Lantheus in a report on Friday, September 29th. They issued an “outperform” rating on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Lantheus presently has an average rating of “Buy” and an average price target of $115.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.